Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...

Hims is pivoting after drugmaker Novo Nordisk on Friday said the Food and Drug Administration has determined that the shortage of Wegovy and Ozempic has been resolved. Compounding its challenges in ...

Hims & Hers Health (NYSE:HIMS) fell ~19% in the premarket on Tuesday, even as the telehealth company reported better-than-expected Q4 2024 financials and set its 2025 outlook above consensus during ...

Super Micro has until Tuesday to file delayed financial accounts or risk being delisted by the Nasdaq stock exchange, ...

The telehealth company Hims & Hers has made waves for its Super Bowl ad that plugged its lower-priced form of injectable ...

U.S. stock futures (ES00) (NQ00) weakened after the S&P 500 SPX finished at its lowest level since mid-January. Bitcoin (BTCUSD) traded below $90,000, and the yield on the 10-year Treasury declined.

Shares of Hims & Hers Health tumbled 18% premarket on Tuesday as Wall Street analysts questioned the telehealth provider's lofty sales forecast in the face of looming restrictions on compounded weight ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Hims & Hers Health (HIMS – Research Report) and Novo ...

Investing.com -- Novo Nordisk shares climbed more than 3% premarket on Tuesday after Hims & Hers Health announced it may no ...

Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock ...

Schumacher is stepping down by mutual agreement on Saturday, before leaving the company on May 31. Japanese trading-house stocks rose sharply after Warren Buffett said Berkshire Hathaway's stakes in ...

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...